Sugammadex Medicine 08 December 2020 Extended indication Opheffing van een door rocuronium geïnduceerd neuromusculair blok bij: Volwassenen: voor onmiddellijke opheffing en voor de zgn. 'standaardopheffing'; Kinderen: standaardopheffing. Therapeutic value Possible equal value Total cost Registration phase Registration application pending Product Active substance Sugammadex Domain Neurological disorders Reason of inclusion Generic G Main indication Muscular diseases Extended indication Opheffing van een door rocuronium geïnduceerd neuromusculair blok bij: Volwassenen: voor onmiddellijke opheffing en voor de zgn. 'standaardopheffing'; Kinderen: standaardopheffing. Current proprietary name Bridion (MSD) Already available biosimilars / generics Proprietary name Manufacturer Portfolio holder Mechanism of action Unknown Route of administration Unknown Therapeutical formulation Unknown Budgetting framework Unknown Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP Unknown Submission date May 2020 Expected Registration August 2021 Orphan drug Unknown Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks SPC van kracht tot en met 28 juli 2023 Therapeutic value Current treatment options Therapeutic value Possible equal value This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks